Fig. 4: Responses to P-BCMA-ALLO1 treatment in RRMM: impact of BM trafficking and effector cell differentiation. | Nature Communications

Fig. 4: Responses to P-BCMA-ALLO1 treatment in RRMM: impact of BM trafficking and effector cell differentiation.

From: TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

Fig. 4

A Treatment timeline for the Phase I trial of P-BCMA-ALLO1 (NCT04960579), including LD administered from days -5 to -3 prior to P-BCMA-ALLO1 infusion on day 0. B ORR by treatment arm. C CK for Arms S, A, and B at the 2 × 106 cells/kg target dose, with Cmax typically achieved between days 7 and 14. D Median Cmax, Tmax, and AUC, highlighting a significant increase in Cmax and AUC in Arm B compared to S (n = 5-8 per treatment arm). E CAR-T cell phenotype tracking from peripheral blood over time, showing differentiation from a largely undifferentiated TSCM phenotype to more TEFF cells, aligned with CAR-T cell expansion. F Analysis of CAR-T cells in the BM, showing a significant proportion differentiating into TEFF cells. All error bars in (D) indicate range. Statistical analysis in (B) used Fisher’s exact test, and (D) employed Kruskal-Wallis one-way ANOVA with Dunn’s test for pairwise comparison. *: p ≤ 0.05, **: p ≤ 0.01. Source data are provided as a Source Data file.

Back to article page